Iparomlimab

Phase 2Monoclonal antibody

TTianjin Medical University Cancer Institute and Hospital

Iparomlimab is one of 59 small molecule programs targeting Head and Neck Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck CancerRecruiting

Locally Advanced Rectal Cancer (LARC)Not yet recruiting

Colon CancerRecruiting

Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Not yet recruiting

Urologic NeoplasmsNot yet recruiting

Ovarian CancersNot yet recruiting

ChemoradiationRecruiting

Head and Neck CancerPhase 2

Recruiting

Locally Advanced Rectal Cancer (LARC)Preclinical

Not yet recruiting

Colon CancerPhase 2

Recruiting

Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Phase 2

Not yet recruiting

Urologic NeoplasmsPhase 2

Not yet recruiting

Ovarian CancersPhase 2

Not yet recruiting

ChemoradiationPhase 2

Recruiting

Competition

Competitive Landscape

42 competitors in Head and Neck Cancer

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Erbitux

IImclone

Phase 3

46 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

64 4

Neurontin

VViatris Specialty LLC

Approved

4 5

Oxycontin

PProtega

Approved

2 6

Opdivo

Bristol-Myers Squibb

Phase 3

10 7

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 8

Marcaine

IInnocoll

Approved

1 9

Tylenol

KKenvue Brands

Approved

1 10

Paraplatin

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Chemoradiation

NCT07038629

Q4 2028

ApprovedRecruiting

Biliary Tract Cancer (BTC)

NCT07619235

Q2 2029

Phase 2Not yet recruiting

Ovarian Cancers

NCT07663513

Q3 2029

Phase 2Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

NCT07776639

Clinical

Trials by Indication[1]

Not yet recruiting·PPeking University Cancer Hospital & Institute·Approved·NCT07854522·76 enrolled

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

A Single-Arm, Prospective, Open-Label Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT07828873·34 enrolled

Locally Advanced Rectal Cancer (LARC)1 trial

Iparomlimab and Tuvonralimab（QL-1706）Combined With Chemotherapy and Bevacizumab With or Without Radiotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer：A Multicenter, Single Arm Clinical Trial

Not yet recruiting·ZZhejiang University·Preclinical·NCT07769853·56 enrolled

6 more indications

Biliary Tract Cancer (BTC)1 trial

A Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

Recruiting·XXianglin Yuan·Approved·NCT07619235·32 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

A Single-Arm, Prospective, Open-Label Clinical Study of Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

Active, not recruiting·YYongxu Jia·Phase 2·NCT07776639·34 enrolled

Urologic Neoplasms1 trial

A Prospective, Single-Arm, Multicenter Clinical Study of Epalolitoworelimab (a PD-1/CTLA-4 Combination Antibody) Combined With Lenvatinib in the Perioperative Treatment of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma

Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT07741617·54 enrolled

Colon Cancer1 trial

Efficacy and Safety of Conversion Therapy for pMMR/MSS T4M0 Colon Cancer Patients Treated With Radiotherapy and Systemic Therapy: a Prospective, Open-label, Multi-center, Randomized Controlled Trial（Neo-Color）

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT06949111·128 enrolled

Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)1 trial

A Prospective, Randomized, Controlled Clinical Trial of Iparomlimab and Tuvonralimab Injection (QL1706) Plus Lenvatinib and Chemotherapy as First-Line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Not yet recruiting·WWest China Hospital·Phase 2·NCT07738159·92 enrolled

Ovarian Cancers1 trial

Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer: A Prospective, Single-Arm, Phase II Study

Not yet recruiting·FFudan University·Phase 2·NCT07663513·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Iparomlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iparomlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iparomlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Medical University Cancer Institute and Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: TTianjin Medical University Cancer Institute and Hospital

Iparomlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Q2 2029

Q3 2029

Trials by Indication[1]

Chemoradiation1 trial

Head and Neck Cancer1 trial

Melanoma1 trial

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

Locally Advanced Rectal Cancer (LARC)1 trial

Biliary Tract Cancer (BTC)1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Urologic Neoplasms1 trial

Colon Cancer1 trial

Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)1 trial

Ovarian Cancers1 trial

References

Drug Info

Quick Facts

Related News